Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

This study is comparing two chemotherapy regimens — R-CMOP (which uses a different drug called mitoxantrone instead of doxorubicin) versus standard R-CHOP — as initial treatment for adults with diffuse large B-cell lymphoma (DLBCL), a common and aggressive type of blood cancer. **You may be eligible if...** - You are between 18 and 80 years old - You have newly diagnosed DLBCL confirmed by biopsy - You have not yet received any treatment for DLBCL - You have at least one measurable tumor and are in reasonably good health (ECOG 0–2) - Your international prognostic score (IPI) is 2 or lower (indicating lower risk) **You may NOT be eligible if...** - You have a different subtype of large B-cell lymphoma or DLBCL that has transformed from another cancer - Your cancer has spread to the brain or spinal cord - You have HIV or AIDS - You are pregnant or breastfeeding - You have received prior cancer treatment Talk to your doctor to see if this trial is right for you.